Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 1, 2005 - Issue 4
Submit an article Journal homepage
300
Views
41
CrossRef citations to date
0
Altmetric
Drug Evaluation

Meloxicam in rheumatoid arthritis

Mansoor Ahmed University of Cincinnati, Division of Immunology, Cincinnati, Ohio, USA
,
Dinesh Khanna University of Cincinnati, Division of Immunology, Cincinnati, Ohio, USA; Institute for the Study of Health, Cincinnati, Ohio, USA; VAMC, Cincinnati, Ohio, USA
&
Daniel E Furst David Geffen School of Medicine, Los Angeles, CA, USA. [email protected]
Pages 739-751 | Published online: 30 Nov 2005

Bibliography

  • FRIES JF, MURTAGH KN, BENNETT M, ZATARAIN E, LINGALA B, BRUCE B: The rise and decline of nonsteroidal anti-inflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum. (2004) 50(8):2433–2440.
  • SINGH G, TRIADAFILOPOULOS G: Epidemiology of NSAID-induced gastrointestinal complications. J. Rheumatol. Suppl. (1999) 56:18–24.
  • DEWITT DL, MEADE EA, SMITH WL: PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am. J. Med. (1993) 95(2A):40S-44S.
  • MEADE EA, SMITH WL, DEWITT DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J. Biol. Chem. (1993) 268(9):6610–6614.
  • FITZGERALD GA, PATRONO C: The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. (2001) 345(6):433–442.
  • ENGELHARDT G: Pharmacology of meloxicam, a new nonsteroidal antiinflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br. J. Rheumatol. (1996) 35(Suppl. 1):4–12.
  • ENGELHARDT G, HOMMA D, SCHLEGEL K, UTZMANN R, SCHNITZLER C: Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new nonsteroidal antiinflammatory agent with favourable gastrointestinal tolerance. Inflamm. Res. (1995) 44(10):423–433.
  • SANO H, HLA T, MAIER JA et al. : In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J. Clin. Invest. (1992) 89(1):97–108.
  • PANARA MR, RENDA G, SCIULLI MG et al. : Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J. Pharmacol. Exp. Ther. (1999) 290(1):276–280.
  • BLAIN H, BOILEAU C, LAPICQUE F et al. : Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br. J. Clin. Pharmacol. (2002) 53(3):255–265.
  • TURCK D, BUSCH U, HEINZEL G, NARJES H: Clinical pharmacokinetics of meloxicam. Arzneimittelforschung (1997) 47(3):253–258.
  • MELOXICAM: Package insert.
  • TURCK D, BUSCH U, HEINZEL G, NARJES H: Clinical pharmacokinetics of meloxicam. Arzneimittelforschung (1997) 47(3):253–258.
  • BUSCH U, SCHMID J, HEINZEL G et al. : Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab. Dispos. (1998) 26(6):576–584.
  • BUSCH U, ENGELHARDT G: Distribution of [14C]meloxicam in joints of rats with adjuvant arthritis. Drug Exp. Clin. Res. (1990) 16(2):49–52.
  • NARJES H, TURCK D, BUSCH U, HEINZEL G, NEHMIZ G: Pharmacokinetics and tolerability of meloxicam after i.m. administration. Br. J. Clin. Pharmacol. (1996) 41(2):135–139.
  • HUBNER G, SANDER O, DEGNER FL, TURCK D, RAU R: Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. J. Rheumatol. (1997) 24(5):845–851.
  • BUSCH U, HEINZEL G, NARJES H, NEHMIZ G: Interaction of meloxicam with cimetidine, Maalox or aspirin. J. Clin. Pharmacol. (1996) 36(1):79–84.
  • TURCK D, SU CA, HEINZEL G, BUSCH U, BLUHMKI E, HOFFMANN J: Lack of interaction between meloxicam and warfarin in healthy volunteers. Eur. J. Clin. Pharmacol. (1997) 51(5):421–425.
  • WOJTULEWSKI JA, SCHATTENKIRCHNER M, BARCELO P et al. : A six-month doubleblind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br. J. Rheumatol. (1996) 35(Suppl. 1):22–28.
  • LEMMEL EM, BOLTEN W, BURGOS-VARGAS R et al. : Efficacy and safety of meloxicam in patients with rheumatoid arthritis. J. Rheumatol. (1997) 24(2):282–290.
  • REGINSTER JY, DISTEL M, BLUHMKI E: A double-blind, 3-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. Br. J. Rheumatol. (1996) 35(Suppl. 1):17–21.
  • FURST DE, KOLBA KS, FLEISCHMANN R et al. : Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12-week multicenter, double blind, dose response study versus placebo and diclofenac. J. Rheumatol. (2002) 29(3):436–446.
  • HUSKISSON EC, GHOZLAN R, KURTHEN R, DEGNER FL, BLUHMKI E: A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br. J. Rheumatol. (1996) 35(Suppl. 1):29–34.
  • FOELDVARI I, BURGOS-VARGAS R, THON A, TUERCK D: High response rate in the Phase I/II study of meloxicam in juvenile rheumatoid arthritis. J. Rheumatol. (2002) 29(5):1079–1083.
  • DUFFY CM, DUFFY KN: Health assessment in the rheumatic diseases of childhood. Curr. Opin. Rheumatol. (1997) 9(5):440–447.
  • RUPERTO N, MARTINI A: International research networks in pediatric rheumatology: the PRINTO perspective. Curr. Opin. Rheumatol. (2004) 16(5):566–570.
  • RUPERTO N, NIKISHINA I, PACHANOV ED et al. : A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum. (2005) 52(2):563–572.
  • RUPERTO N, NIKISHINA I, PACHANOV ED, SHACHBAZIAN Y, PRIEUR AM, MOUY R et al. : A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum. (2005) 52(2):563–572.
  • DISTEL M, MUELLER C, BLUHMKI E, FRIES J: Safety of meloxicam: a global analysis of clinical trials. Br. J. Rheumatol. (1996) 35(Suppl. 1):68–77.
  • SCHOENFELD P: Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am. J. Med. (1999) 107(6A):48S–54S.
  • SINGH G, LANES S, TRIADAFILOPOULOS G: Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am. J. Med. (2004) 117(2):100–106.
  • HAWKEY C, KAHAN A, STEINBRUCK K et al. : Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br. J. Rheumatol. (1998) 37(9):937–945.
  • DEQUEKER J, HAWKEY C, KAHAN A et al. : Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COXinhibiting Therapies (SELECT) trial in osteoarthritis. Br. J. Rheumatol. (1998) 37(9):946–951.
  • BOMBARDIER C, LAINE L, REICIN A et al. : Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. (2000) 343(21):1520–1528.
  • SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al. : Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA (2000) 284(10):1247–1255.
  • HAWKEY CJ, FARKOUH M, GITTON X, EHRSAM E, HUELS J, RICHARDSON P: Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics. Aliment Pharmacol. Ther. (2004) 20(1):51–63.
  • PATOIA L, SANTUCCI L, FURNO P et al. : A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br. J. Rheumatol. (1996) 35(Suppl. 1):61–67.
  • CHANG DM, YOUNG TH, HSU CT, KUO SY, HSIEH TC: Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis. Clin. Rheumatol. (2001) 20(2):104–113.
  • LANZA F, PANAGIDES J, SALOM IL: Etodolac compared with aspirin: an endoscopic study of the gastrointestinal tracts of normal volunteers. J. Rheumatol. (1986) 13(2):299–303.
  • BEVIS PJ, BIRD HA, LAPHAM G: An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Br. J. Rheumatol. (1996) 35(Suppl. 1):56–60.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.